Inovio Closes License, Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China; Will Receive $23M Upfront And An Additional $20M In Future Regulatory Milestone Payments Along With A Double-Digit Royalty Future Sales